Cangrelor for the management and prevention of arterial thrombosis

References

• Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016. [Epub ahead of print].
   Google Scholar
• Underwood JCE, Cross SS. General and systematic pathology. Edinburgh: Elsevier Churchill Livingstone; 2009. p. 857.
   Google Scholar
• West LE, Steiner T, Judge HM, et al. Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovasc Res. 2014;102:429–435.
   PubMed Web of Science ®Google Scholar
• Stalker TJ, Traxler EA, Wu J, et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood. 2013;121:1875–1885.
   PubMed Web of Science ®Google Scholar
• Chen J, Lopez JA. Interactions of Platelets with subendothelium and endothelium. Microcirculation. 2005;12:235–246.
   PubMed Web of Science ®Google Scholar
• Storey RF. Antiplatelet therapy: Cangrelor succeeds, at last, in PCI. Nat Rev Cardiol. 2013;10:302–304.
   PubMed Web of Science ®Google Scholar
• Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des. 2006;12:1255–1259.
   PubMed Web of Science ®Google Scholar
• Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113:340–345.
   PubMed Web of Science ®Google Scholar
• Thomas MR, Outteridge SN, Ajjan RA, et al. Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model. Arteriosclerosis Thromb Vasc Biol. 2015;35:2562–2570.
   PubMed Web of Science ®Google Scholar
• Sambrano GR, Weiss EJ, Zheng YW, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001;413:74–78.
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thromb Haemost. 2011;105(Suppl 1):S67–74.
   Google Scholar
• Daniel JL, Dangelmaier C, Jin J, et al. Molecular basis for ADP-induced platelet activation: I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998;273:2024–2029.
   PubMed Web of Science ®Google Scholar
• MacKenzie A, Mahaut-Smith MP, Sage SO. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets. J Biol Chem. 1996;271:2879–2881.
   PubMed Web of Science ®Google Scholar
• Trumel C, Payrastre B, Plantavid M, et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR-1 activating peptide through the late activation of phosphoinositide 3-kinase. Blood. 1999;94:4156–4165.
   PubMed Web of Science ®Google Scholar
• Nicholas RA. Identification of the P2Y12 receptor: a novel member of the P2Y family of receptors activated by extracellular nucleotides. Mol Pharmacol. 2001;60:416–420.
   PubMed Web of Science ®Google Scholar
• Storey RF, Sanderson HM, White AE, et al. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110:925–934.
   PubMed Web of Science ®Google Scholar
• Andre P, Delaney SM, LaRocca T, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003;112:398–406.
   PubMed Web of Science ®Google Scholar
• Cosemans JMEM, Munnix ICA, Wetzker R, et al. Continuous signaling via PI3K isoforms β and  is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood. 2006;108:3045–3052.
   PubMed Web of Science ®Google Scholar
• Patil SB, Jackman LE, Francis SE, et al. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Arteriosclerosis Thromb Vasc Biol. 2010;30:2385–2391.
   PubMed Web of Science ®Google Scholar
• Fagura MS, Dainty IA, McKay GD, et al. P2Y1-receptors in human platelets which are pharmacologically distinct from P2YADP-receptors. Br J Pharmacol. 1998;124:157–164.
   PubMed Web of Science ®Google Scholar
• Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med. 2008;5:766–780.
   PubMedGoogle Scholar
• Muller C, Buttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation. 2000;101:590–593.
   PubMed Web of Science ®Google Scholar
• Storey RF. Clopidogrel in acute coronary syndrome: to genotype or not? Lancet. 2009;373:276–278.
   PubMed Web of Science ®Google Scholar
• Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost. 1996;76:939–943.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSet of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–2585.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Storey RF. Development and clinical use of prasugrel and ticagrelor. Curr Pharm Des. 2012;18:5240–5260.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627–635.
   PubMed Web of Science ®Google Scholar
• Fuller EE, Alemu R, Harper JF, et al. Relation of nausea and vomiting in acute myocardial infarction to location of the infarct. Am J Cardiol. 2009;104:1638–1640.
   PubMed Web of Science ®Google Scholar
• Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601–1606.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment–elevation myocardial infarction. Circulation: Cardiovas Interventions. 2012;5:797–804.
   PubMed Web of Science ®Google Scholar
• Thomas MR, Morton AC, Hossain R, et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost. 2016;116. Epub
   Web of Science ®Google Scholar
• Silvain J, Storey RF, Cayla G, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost. 2016;116. online
   PubMedGoogle Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of Platelet Inhibition with Cangrelor during PCI on ischemic events. New England J Med. 2013;368:1303–1313.
   PubMed Web of Science ®Google Scholar
• Ingall AH, Dixon J, Bailey A, et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem. 1999;42:213–220.
   PubMed Web of Science ®Google Scholar
• Judge HM, Buckland RJ, Holgate CE, et al. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets. 2005;16:398–407.
   PubMed Web of Science ®Google Scholar
• Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014;384:1849–1858.
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. New England J Med. 2008;358:2218–2230.
   PubMed Web of Science ®Google Scholar
• Armstrong D, Summers C, Ewart L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209–219.
   PubMed Web of Science ®Google Scholar
• Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001;85:401–407.
   PubMed Web of Science ®Google Scholar
• Cohen MV, Downey JM. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol. 2015;172:1913–1932.
   PubMed Web of Science ®Google Scholar
• Yang XM, Cui L, White J, et al. Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion. Basic Res Cardiol. 2015;110:3.
   PubMed Web of Science ®Google Scholar
• Bell RM, Sivaraman V, Kunuthur SP, et al. Cardioprotective properties of the platelet p2y12 receptor inhibitor, cangrelor: protective in diabetics and reliant upon the presence of blood. Cardiovasc Drug Ther. 2015;29:415–418.
   PubMed Web of Science ®Google Scholar
• Jacobsson F, Swahn E, Wallentin L, et al. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther. 2002;24:752–765.
   PubMed Web of Science ®Google Scholar
• Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002;13:407–413.
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F, Tello-Montoliu A, et al. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. JACC Cardiovasc Interv. 2014;7:426–434.
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006;151:689.e1–689.e10.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial. J Am Med Assoc. 2012;307:265–274.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121:527–534.
   PubMed Web of Science ®Google Scholar
• Schneider DJ, Seecheran N, Raza SS, et al. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015;26:42–48.
   PubMed Web of Science ®Google Scholar
• Judge HM, Patil SB, Buckland RJ, et al. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J Thromb Haemostasis. 2010;8:1820–1827.
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2015;37:267–315.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21–30.
   PubMed Web of Science ®Google Scholar
• Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel s active metabolite. J Thromb Haemost. 2007;5:1545–1551.
   PubMed Web of Science ®Google Scholar
• Judge HM, Buckland RJ, Jakubowski JA, et al. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro. Platelets. 2016;27:191–195.
   PubMed Web of Science ®Google Scholar
• Dovlatova N, Jakubowski J, Sugidachi A, et al. The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemostasis. 2008;6:1153–1159.
   PubMed Web of Science ®Google Scholar
• Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC: Cardiovasc Intervent. 2014;7:435–442.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34:44–55.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. New England J Med. 2009;361:2330–2341.
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. New England J Med. 2009;361:2318–2329.
   PubMed Web of Science ®Google Scholar
• White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163:182–190.
   PubMed Web of Science ®Google Scholar
• Leonardi S, Truffa AA, Neely ML, et al. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013;99:1282–1287.
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382:1981–1992.
   PubMed Web of Science ®Google Scholar